Juvenile Idiopathic Arthritis

  • Patience H. White
  • Patricia Woo
  • Carol B. Lindsley


Juvenile idiopathic arthritis (JIA) is an umbrella term for a group of persistent arthritides of unknown etiology that affect children under the age of 16, and last for more than 6 weeks (Petty et al. 2004). The clinically defined categories are shown in Table 4.1. The pathogenesis of these diseases involves both autoimmune and genetic factors. Dysregulation of the immune and inflammatory systems are observed. In addition, hormonal, infectious, and other environmental agents yet to be identified probably participate in the disease-diagnosing process. The diagnosis of JIA is rendered from the combination of data derived from the history, physical examination, and laboratory testing. The prevalence of JIA varies depending on subtypes. As a group, the prevalence is generally agreed to be 1:1,000 children. For the vast majority of patients with JIA, the immuno-genetic associations, clinical course and functional outcome are quite different from adult-onset rheumatoid arthritis. In addition, certain specific disease subsets are not observed at all or are seen very rarely in adults. These subsets include the oligoarticular pattern of arthritis associated with uveitis and antinuclear antibodies, and sJIA (sJIA). Most patients with JIA do not achieve a remission and require long-term treatment. However, the use of new therapies such as methotrexate and the biologic agents has improved the outcome of JIA.


Juvenile Idiopathic Arthritis Psoriatic Arthritis Juvenile Idiopathic Arthritis Patient Macrophage Activation Syndrome Polyarticular Juvenile Idiopathic Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Cabral DA, Tucker LB. Malignancies in children who initially present with rheumatic complaints. J Pediatr 1999; 1345:53–57Google Scholar
  2. Cassidy J, Kivlin J, Lindsley C, Nocton J. Opthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 2006; 117:1843–1845PubMedCrossRefGoogle Scholar
  3. Ferucci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, Passo M, Thompson SD, Deane KD, Rewers M, Arend WP, Glass DN, Norris JM, Holers VM. Arthritis Rheum. 2005 Jan;52(1):239–46PubMedCrossRefGoogle Scholar
  4. Huerta-Sil G, Casasola-Vargas JC, Londoño JD, et al Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spon-dylitis throughout follow up. Ann Rheum Dis 2006; 65(5):642–646CrossRefGoogle Scholar
  5. Jarvis JN, Petty HR, Tang Y, et al Evidence for chronic peripheral activation of neutrophils in polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther 2006; 8:R154PubMedCrossRefGoogle Scholar
  6. Lambert JR, Wright V. Psoriatic spondylitis: a clinical and radiological description of the spine in psoriatic arthritis. QJ Med 1977; 46(184): 411–425Google Scholar
  7. Lequerre T, Quartier P, et al Interleukin-1 receptor anatagonist treatment in patients with systemic-onset juvenile idiopathicarthiritis or adult onset Still dieases: Preliminary experience in France. Ann Rheum Dis 2008; 67:281–282Google Scholar
  8. Lovell DJ. Update on treatment of arthriits in children: New treatment, new goals. Bull NYU Hosp Jt Dis 2006; 64 (1–2):72–76PubMedGoogle Scholar
  9. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P. International League of Associations for Rheumatology. J Rheumatol 2004 Feb; 31(2):390–392PubMedGoogle Scholar
  10. Prahalad S, Glass DN. A comprehensive review of the genetics of juvenile idiopathic arthritis. Paedr Rheumatol Online J 2008; 6:11CrossRefGoogle Scholar
  11. Robertson DM, Cabral DA, Malleson PN, Petty RE. Juvenile psoriatic arthritis: Follow-up and evaluation of diagnostic criteria. J Rheumatol 1989; 32:1007–1013Google Scholar
  12. Rosenberg A, Oen K. The relationship between ocular and articular disease activity in children with JRA and associated uveitis.Arthritis Rheum. 1986; 29:797PubMedCrossRefGoogle Scholar
  13. Stephen JL, Zeller J, Hubert PH, et al Macrophage Activation syndrome and rheumatic disease in childhood: A report of four cases. Clin Exp Rheumatol 1993; 11:451–456Google Scholar
  14. Stoll ML, Zurakowski D, Nibrovic LE, et al Patients with juvenile pso-riatic arthritis comprise two distinct populations. Arthritis Rheum 2006; 54:3564–3572PubMedCrossRefGoogle Scholar
  15. Woo, P. Systemic juvenile idiopathic arthritis. Nat Clin Pract Rheumatology 2006; 2:28–34CrossRefGoogle Scholar
  16. Yokota S, Imagawa T, Mori M, et al Efficacy and safety of tocilizumab in patients with systemic onset juvenile idiopathic arthritis: A randomised double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008 Mar 22; 371(9617):998–1006PubMedCrossRefGoogle Scholar
  17. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008; 58:2892–2896.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Patience H. White
    • 1
  • Patricia Woo
    • 2
  • Carol B. Lindsley
    • 3
  1. 1.Department of Public HealthArthritis FoundationWashington, D.C.USA
  2. 2.Centre for Paediatric and Adolescent RheumatologyUniversity College LondonLondonEngland
  3. 3.Chief Pediatric RheumatologyUniversity of Kansas Medical Center, PediatricsKansas CityUSA

Personalised recommendations